Red blood cells and megakaryocytes arise from a common precursor, the megakaryocyte-erythroid progenitor and share many regulators including the transcription factors GATA-1 and GFI-1B and signaling molecules such as JAK2 and STAT5. These lineages also share the distinction of being associated with rare, but aggressive malignancies that have very poor prognoses. In this review, we will briefly summarize features of normal development of red blood cells and megakaryocytes and also highlight events that lead to their leukemic transformation. It is clear that much more work needs to be done to improve our understanding of the unique biology of these leukemias and to pave the way for novel targeted therapeutics.
Development of erythroid cells
Commitment of hematopoietic stem cells/early progenitors to the erythroid lineage takes place within the bone marrow microenvironment under the influence of multiple regulatory factors. Pleotrophic and lineage-specific cytokines play a key role in the commitment and differentiation of erythroid cells (Figure 1 ). In addition, transcription factors, the bone marrow microenvironment and numerous signaling proteins also play a vital function in guiding and promoting expansion and differentiation of erythroid progenitors. During the past two decades, especially since the discovery of erythropoietin in mid-1980s, it has been possible to systematically study the contribution of various transcription factors and signaling proteins in the expansion and differentiation of erythroid progenitors into mature circulating erythroid cells (Cantor and Orkin, 2002; Koury et al., 2002) . These studies have greatly contributed to our understanding of regulatory factors responsible for both erythroid cell expansion as well as differentiation.
Accumulated evidence mostly from studies with mouse models and human primary cells suggests that cellular expansion and differentiation occur concurrently until the late stages of erythroid differentiation (polychromatic/orthochromatic) at which point the cells exit the cell cycle and undergo terminal maturation (Wickrema et al., 1992; Ney and D'Andrea, 2000; Koury et al., 2002) . A disruption of the balance between erythroid cell expansion and differentiation results in either myeloproliferative disorders (MPDs) such as polycythemia vera, myelodysplastic syndrome, or rarely in erythroleukemia. Furthermore, some patients initially diagnosed with MPDs ultimately progress to erythroleukemia. In this first part of the review, we will highlight key factors that regulate the erythroid differentiation program and their contribution to erythroleukemia.
Clinical characteristics of erythroleukemia
Erythroleukemia is a relatively rare disease in humans accounting for approximately 5% of all acute myeloid leukemia (AML). The disease is more prevalent in males, and 50% of all cases are considered therapyrelated leukemias due to prior exposure to chemotherapy or immunosuppressive agents. In addition, some cases occur as end-stage transformation of myelodysplastic syndrome. The disease has a bimodal distribution with a small peak in patients under the age of 20 and an increasing incidence in patients over the age of 70. Patients typically present with fatigue and anemia and occasional hepato-or splenomegaly. The large majority of patients have cytogenetic abnormalities in the bone marrow, many of them associated with an adverse prognosis (such as deletions of chromosome 5 or 7) (Michiels et al., 1997; Park et al., 2002) . Unlike chronic myelogenous leukemia, there is no single characteristic cytogenetic abnormality associated with erythroleukemia. The diagnosis is established by examination of the peripheral blood and bone marrow, which is hypercellular and commonly displays trilineage dysplasia. Two subtypes of acute erythroleukemia are recognized in the current World Health Organization classification: erythroleukemia (erythroid/myeloid), also commonly named M6a, is defined by the presence in the bone marrow of >50% erythroid precursors in the entire nucleated cell population and >20% myeloblasts in the non-erythroid population, (that is, the myeloblasts are calculated as a percentage of the non-erythroid bone marrow cells). The second subtype, pure erythroleukemia, also known as M6b, represents a neoplastic proliferation of immature cells committed exclusively to the erythroid lineage (>80% of marrow cells) with no evidence of a significant myeloid component (Jaffe, 2001) . Cytochemical stains sometimes show aberrant periodic acid Schiff (PAS) positivity in erythroid precursors, while Prussian blue stains demonstrate increased iron stores and sometimes ringed sideroblasts. Immunophenotyping gives variable results, however, the classic erythroid markers glycophorin A and CD71 (transferrin receptor) are useful in classification of ambiguous cases.
Treatment for patients with erythroleukemia is similar to that of other AML patients, but their outcome tends to be poor, with the majority of patients relapsing after an initial response. Allogeneic bone marrow transplantation is considered a curative treatment, although its use is limited by comorbidities in elderly patients and by lack of suitable donors. Erythroleukemia is a rare disease, and as a result relatively few clinical samples have been available for research. The ability to study primary erythroleukemia in vitro has been further hampered by the fact that most erythroleukemic patients have their myeloid compartment also affected by leukemia. Therefore, much of the research has been performed using mouse models or human cell lines.
Transformation of human erythroid cells
Transformation of normal erythroid progenitors to leukemia cells is a multistep process that occurs over a long period of time. It is characterized by expansion of erythroid progenitors at the expense of terminal differentiation and can occur at any of the distinct stages of erythroid maturation. For example, minimally differentiated erythroleukemia includes cells that are mostly at early stages after commitment to erythroid lineage (burst-forming unit erythroid, BFU-E). Such immature erythroleukemia cells exhibit an HLADRÀ/CD36 þ phenotype. On the other hand, erythroleukemia affecting the late stages of maturation (colony-forming unit erythroid, CFU-E), exhibit more mature morphology and are generally positive for glycophorin A (Park et al., 2002) . Although the molecular mechanisms underlying the transformation of erythroid cells into erythroleukemia in humans are not well understood, cell lines generated from patient samples have been quite useful in characterizing some of the key biochemical and cellular characteristics of this malignancy. Approximately 21 human erythroleukemia cell lines have been utilized in studies to understand the proliferation and differentiation program of the erythroid lineage (Drexler et al., 2004) . The best-known one is the K562 cell line, which has been extensively used over the last 25 years to study the 'normal' erythroid differentiation program, Figure 1 A model for human erythroid cell development and potential factors influencing the transformation into erythroleukemia. The scheme outlines the stages of maturation and cytokine requirements at each stage of erythroid differentiation in addition to temporal expression pattern of transcription factors during differentiation. Expression pattern of cytokine receptors (in parentheses) and stage-specific activation of signal transduction proteins are also depicted in the scheme. Morphological changes in size, shape and color (due to hemoglobin) are indicated as part of the differentiation program. Aberrant expression of transcription factors and activation of signaling proteins in human and/or murine erythroleukemia are shown in bold italics (red).
but which originated from a patient with chronic myelogenous leukemia in blasts crisis (and thus expresses the BCR/ABL fusion protein). These available erythroleukemia cell lines exhibit a wide range of functional characteristics such as variable cytokine requirements and differing abilities to differentiate in culture with or without differentiation agents. Therefore, despite their common use for this purpose, these cell lines are not particularly accurate models for the study of the normal differentiation program of erythroid cells. With the discovery of c-kit-ligand (stem cell factor) and improved methodologies to isolate CD34 þ early progenitors from healthy individuals, it is now possible to expand and differentiate large numbers of primary erythroid progenitors. This approach allows us to study the differentiation program of human erythroid cells under more physiological conditions (Freyssinier et al., 1999; Uddin et al., 2004; Giarratana et al., 2005) . The knowledge of cytokine requirements and the regulation of transcription factor expression learned by studying the normal differentiation program in primary cells can then be applied to gain insights into the molecular program of erythroleukemia. Nevertheless, our understanding of multistep transformation process in human erythroid progenitors remains incomplete. At present this process has been most elegantly studied in mice and chicken using retroviral-infected primary erythroid progenitors.
Transformation of murine and avian erythroid progenitors Transformation of normal avian and murine erythroid cells to erythroleukemia occurs in a multistep process as a result of infection by retroviruses (Ney and D'Andrea, 2000; Rietveld et al., 2001) . Even though erythroleukemia in humans has not been associated with a specific viral infection, studies performed using avian and murine model systems have provided a great deal of insight into the molecular events involved in progression of erythroblastosis to erythroleukemia. In the case of avian erythroleukemia, E26 retrovirus is responsible for severe erythroblastosis that rapidly progresses to erythroleukemia (Sotirov, 1981; Samarut and Gazzolo, 1982) . This avian virus contains the human homologs of myb and ets-1 genes, which are responsible for transformation of avian erythroblasts. In the case of murine erythroleukemia, Friend virus is responsible for progression of erythroblastosis to murine erythroleukemia (Friend, 1957) . The Friend virus has two variants, the spleen focus-forming virus (SFFV) polycythemia strain (SFFV-P) and SFFV anemia strain (SFFV-A). The pathogenicity of SFFV is due to the envelope protein gp55, which binds the erythropoietin (Epo) receptor and activates it in the absence of Epo (Blair and Athanasiou, 2000; Ney and D'Andrea, 2000) . Both SFFV polycythemia and SFFV anemia strains cause disease in the erythroid lineage although they act quite differently. In the case of infection by SFFV polycythemia strain, the mice become polycythemic, whereas mice infected with SFFV anemia strain become anemic.
The differences in the manifestation of the disease in these two strains are due to differences in a few amino acids within the gp55 protein (Chung et al., 1989; Fang et al., 1998) . Mice infected with SFFV anemia strain exhibit clonal expansion with terminal differentiation in the presence of Epo. During the initial stage of infection, erythroid progenitors are found mostly at the colonyforming unit erythroid stage of differentiation, and the spleens of these mice are enlarged due to accumulation of colony-forming unit erythroids. However, as the Friend disease progresses, the leukemic clones emerge and yield a preponderance of mouse erythroleukemia cells. The molecular mechanisms involved in this transformation have been studied extensively. Of note, erythroid progenitors obtained during the initial phase of infection with SFFV-A have been used to study the molecular program of terminal erythroid differentiation, especially because they respond to Epo during in vitro culture and terminally differentiate to reticulocytes (Koury et al., 1984; Wickrema et al., 1991) . Prior to development of model systems to study human erythroid differentiation in vitro this was one of the few primary in vitro cell culture systems that were available to study the molecular program of late stage erythropoiesis.
One of the proteins involved in the leukemic transformation in mice is the gene product of spi-1, PU.1. PU.1 belongs to the E26 transformation specific (ETS) family of transcription factors, which are also known to play a role in avian erythroleukemia (Blair and Athanasiou, 2000) . On the basis of a large number of studies on the role of PU.1, it is well established that in order for erythroid progenitors to continue their normal differentiation program PU.1 expression must be switched off very early at the time of commitment of the erythroid lineage. Chromosomal rearrangements that occur due to infection by retroviruses such as SSFV affect Spi-1/PU.1 expression in mice, and contribute to leukemogenesis (Kosmider et al., 2005) . Although previous studies have clearly shown that PU.1 blocks differentiation, these recent studies in spi-1 transgenic mice indicate that PU.1 also impacts Epo-mediated cell survival through AKT and STAT5 signaling pathways. In addition to PU.1, several other transcription regulators have been implicated in promoting erythroleukemia in mice as a result of chromosomal rearrangements. One such transcriptional regulator is FLI-1, another member of the ETS family of transcription factors. FLI-1 induces erythroleukemia in newborn mice (as a result of infection by a component of the Friend virus) as opposed to in adult mice in the case of PU.1 (Blair and Athanasiou, 2000) . Nevertheless, expression of these transcriptional regulators alone is not sufficient to produce erythroleukemia in mice. Subsequent genetic alterations and/or loss of genes such as p53 is necessary for erythroleukemia to develop, reaffirming the notion that leukemogenesis is a multistep process that occurs over time. PU.1 and FLI-1 are the best-studied transcription factors in the context of viral-induced erythroleukemia, but other transcription factors, especially those that promote expansion and/or differentiation, are likely to be important as well in human erythroleukemia.
Regulatory pathways and molecules influencing erythroid transformation Rearrangement, deletions and/or specific mutations in human and mouse chromosomes can result in clonal expansion and subsequent transformation to erythroleukemia. In order for erythroleukemia to emerge, one or more molecules regulating erythroid differentiation must be affected. However, recent data also indicate leukemogenesis of a particular lineage may arise as a result of altered balance or expression of a transcription factor that regulates a lineage besides the one that is affected by leukemia (Cantor and Orkin, 2002) .
Transcription factors influencing erythroleukemia. A large number of transcription factors guide the expansion and differentiation of committed erythroid progenitors during normal erythropoiesis. Although lineagespecific transcription factors are pivotal in induction of the commitment and subsequent progression of the differentiation process, transcription factors that are important for guiding other hematopoietic lineages also play a role in manifestation of erythroleukemia, such as in mice infected with the Friend virus. There is now direct evidence for involvement of transcription factors that promote erythroid proliferation in the development of erythroleukemia. In a recent study, STAT1 and STAT3 transcription factors were found to be constitutively activated in primary erythroleukemia cells (Kirito et al., 2002) . The same study also showed that mutation of STAT-binding sites within the c-myc gene promoter was able to block promoter activity, suggesting that c-myc activation may contribute to the proliferative potential of the malignant clone in erythroleukemia. Another transcription factor that has been implicated in erythroid leukemia is the growth factor-independent 1B protein (GFI-1B). In a recent study, it was demonstrated that patients with AML M6 and AML M7 (acute megakaryocytic leukemia (AMKL, see below) express high levels of GFI-1B mRNA in bone marrow cells (Elmaagacli et al., 2007) . Furthermore, this report also demonstrated a decrease in the proliferative capacity of K562 and HEL after silencing GFI-1B expression using siRNA. However, other hematologic malignancies such as chronic myelogenous leukemia and other AMLs did not exhibit an increased level of GFI-1B expression. In normal erythropoiesis, GFI-1B has been shown to play a vital role in both promoting differentiation as well as expansion of early committed erythroid progenitors (Osawa et al., 2002; Saleque et al., 2002; Garcon et al., 2005) . Figure 1 summarizes the expression pattern of transcription factors important in the erythroid maturation and highlights those that have been implicated in human erythroleukemia. In addition to transcription factors promoting proliferation, a number of transcription factors have been identified that only promote erythroid commitment and terminal differentiation. Among them GATA1/2, SCL/TAL, NF-E2 and EKLF have been extensively studied using transgenic mice and cell lines. Differentiation blocks due to deletion of GATA1, SCL/ TAL, NF-E2 or EKLF in mice do not result in uncontrolled proliferation or leukemia in vivo, at least based on mouse models where most of the studies have been performed (Aplan et al., 1992; Andrews, 1998; Cantor and Orkin, 2002; Xu et al., 2003; Drissen et al., 2005) . This lack of transformation likely may stem from an additional requirement for these transcription factors in cell survival (for example, Weiss and Orkin, 1995) . Also, many of these transcription factors, such as NF-E2, participate in various aspect of globin gene regulation. Interestingly, integration of the Friend virus within the sequences encoding the p45 subunit of the NF-E2 gene results in a block of erythroid maturation in mice (Lu et al., 1994) . This phenomenon is limited to the Friend disease in mice but has not been implicated in erythroleukemia in humans. In addition to the transcription factors mentioned above, nuclear factor-kB and forkhead transcription factors (FOXO) are expressed during the erythroid differentiation program (Zhang et al., 1998; Mahmud et al., 2002) . The FOXO family of transcription factors has also been implicated in several forms of solid tumors in pediatric patients: in some cases, they form fusion proteins with PAX and inactivate the normal function of FOXO1a (Keller et al., 2004) . Up to now, neither nuclear factor-kB nor FOXO has been directly implicated in erythroleukemia.
Signaling proteins influencing erythroleukemia. Signaling proteins play a central role in leukemogenesis. Involvement of signaling proteins in erythroleukemia occurs as a result of mutations in cytokine receptors, which will result in constitutive activation downstream signaling pathways independent of cytokines. An excellent example is that of JAK2 mutations prevalent in polycythemia vera (Baxter et al., 2005; James et al., 2005; Kralovics et al., 2005; Levine et al., 2005; Zhao et al., 2005) . In SFFV-infected mice, acquisition of specific activating mutations in c-kit also results in clonal expansion of erythroid progenitors (Kosmider et al., 2005) . These activating mutations in receptor tyrosine kinases allow constitutive activation of multiple downstream signaling cascades important in cell proliferation and/or cell survival. In addition to these mechanisms of activation, it has been demonstrated that autocrine or paracrine production of proinflammatory cytokines, such as tumor necrosis factor-a due to oncogenic changes in cells, may provide a proliferative advantage by activating signaling pathways (Jacobs-Helber et al., 2003) . Other studies have shown that Lyn kinase and the signaling intermediate Gab2 also play a role in supporting the growth of erythroleukemia cells. Lyn kinase, which belongs to the Src family of kinases, is involved in normal signaling as well as in the development of erythroleukemia in mice (Tilbrook et al., 2001) , while Gab2, an adaptor protein involved in Epomediated signaling events in normal cells is recruited by the truncated form of Stk tyrosine receptor in Friend virus-infected erythroid cells to promote the expansion of mouse erythroid cells (Wickrema et al., 1999; Teal et al., 2006) . Finally, besides signal transduction proteins that are actively involved in supporting proliferation, it is conceivable that signaling proteins such as phosphatidylinositol 3-kinase and AKT also could support the survival of erythroleukemia cells through constitutive activation of the cell survival pathways.
Normal and malignant megakaryopoiesis
Development of megakaryocytes Similar to erythroid cells, megakaryocytes also arise from the megakaryocyte-erythroid progenitor (MEP) and progress through discrete maturation stages (Figure 2) . Committed megakaryocyte progenitors, including the colony-forming unit megakaryocyte, proliferate to a limited extent, giving rise to promegakaryoblasts. Individual megakaryocytes then undergo terminal differentiation and eventually shed platelets. In concert with cytoplasmic maturation that leads to platelet production, megakaryocyte nuclei undergo a maturation process that involves repeated rounds of DNA synthesis without cell division, a variant cell cycle termed endomitosis (Ravid et al., 2002) . This phenomenon allows megakaryocytes to accumulate DNA content typically up to 64N and greatly increases their size and protein production (Hancock et al., 1993; Raslova et al., 2003) . These increases in cell size, DNA content and protein levels are associated with the development of long cytoplasmic extensions, termed proplatelet forms, that eventually shed platelets (Cramer et al., 1997) . Although it remains unclear whether polyploidization is essential for platelet production, a recent gene profiling study has shown that polyploidization does not directly regulate gene expression per se in megakaryocytes (Raslova et al., 2006) . Megakaryocyte maturation is governed by the activity of a group of transcription factors, including GATA-1, Friend of GATA-1 (FOG-1) and RUNX1, with additional regulation provided by signaling molecules such as JAK and Src family kinases. Many of these same factors are shared between erythroid cells and megakaryocytes, but have distinct targets in the two different settings. Below, we will highlight the roles of these factors in abnormal megakaryopoiesis, with an emphasis on recently published findings and on the relationship between gene expression and leukemic transformation.
Clinical characteristics and classification of acute megakaryocytic leukemia Megakaryocytic leukemias comprise a subgroup of rare, but aggressive, AMLs. There are three main groups of patients who develop distinct forms of AMKL: children with Down syndrome (DS) (DS-AMKL); infants without DS (non-DS pediatric AMKL); and adults. AMKL comprises approximately 5-7% of AML in children without DS (Barnard et al., 2006) and 1% of adult AML (Tallman et al., 2000; Pagano et al., 2002) . In the context of DS, however, megakaryocytic disorders are relatively common, occurring in as many as 10% of newborns. Here, we will address the clinical and genetic features of these intriguing megakaryocytic malignancies.
AMKL in children with DS. Children with DS are predisposed to two related megakaryocytic disorders: transient MPD (TMD) and AMKL. TMD, which is characterized by the expansion of abnormal megakaryoblasts in the peripheral blood and liver, is estimated to occur in nearly 10% of DS newborns, although the majority of cases are subclinical (Zipursky, 2003) . Interestingly, this disease often undergoes spontaneous remission and does not require treatment except in rare cases in which TMD blasts promote severe hepatic fibrosis or cardiopulmonary failure (Al-Kasim et al., 2002) . Although TMD disappears in most cases, it reappears as AMKL in 20-30% of infants diagnosed with more severe cases of TMD. The incidence of AMKL in children with DS is 1 of 500, with a median age of presentation of 2 years, which corresponds to a Figure 2 A model for megakaryocyte development. Megakaryocyte maturation proceeds in an ordered manner from the MEP through proplatelet-producing cells. Important transcriptional and signaling regulators that are required for the initial stages of megakaryopoiesis are indicated above and below the cells, respectively. Genes labeled with an asterisk are either mutated or misexpressed in human megakaryocytic disorders. One of the more interesting areas of megakaryocyte research is the investigation of factors that regulate the choice of a 4N megakaryoblast to undergo cell division and generate two 2N daughter cells, or to commit to polyploidization and proplatelet formation. It is possible that deregulation of this decision may contribute to AMKL. AMKL, acute megakaryocytic leukemia; MEP, megakaryocyte-erythroid progenitor; CFU-Mk, colony forming unit-megakaryocyte; Mk, megakaryocyte.
nearly 500-fold increased risk of AMKL in comparison to children without DS (Lange, 2000) . In contrast to TMD, AMKL is a life-threatening acute leukemia, characterized by the presence of megakaryoblasts in the peripheral blood and bone marrow, and is frequently accompanied by myelofibrosis and thrombocytopenia (Lange, 2000) . DS-AMKL blasts express the myeloid markers CD33 and/or CD13 in addition to at least one platelet-associated antigen (CD36, CD41a, CD41b or CD61). A proportion of these blasts also express erythroid-specific mRNAs, such as g-globin and erythroid d-aminolevulinate synthase, suggesting that they have both erythroid and megakaryocytic properties and perhaps arise from an MEP-like progenitor cell (Ito et al., 1995) .
Mutations in the essential hematopoietic transcription factor GATA1 are associated with nearly all cases of TMD and DS-AMKL, but are not found in any other form of acute leukemia (for a review, see Muntean et al., 2006) . The role of GATA1 mutations and trisomy 21 in the transformation of megakaryocytes is an area of intense research (discussed below). Interestingly, the GATA1 mutation in these leukemic cells may be responsible for their favorable response to chemotherapy: Taub and colleagues (Ge et al., 2004) have shown that DS-AMKL cells express reduced levels of the GATA-1 target gene cytidine deaminase, and as a consequence, the cells are hypersensitive to Ara-C chemotherapy. Indeed, the current treatment regimen has resulted in favorable outcomes for this group of AMKL patients, with an overall survival of 70-80% at 5 years (Gamis, 2005; Al-Ahmari et al., 2006) .
Pediatric non-DS AMKLs. Childhood non-DS AMKL is characterized by an expansion of megakaryoblasts within the bone marrow and is frequently accompanied by myelofibrosis, hepatosplenomegaly and pancytopenia, usually including thrombocytopenia (Carroll et al., 1991; Bernstein et al., 2000; Barnard et al., 2006; Rubnitz et al., 2007) . The majority of infant cases of AMKL are associated with the (1;22) translocation, which was initially discovered in 1991 (Carroll et al., 1991) and recently found to result in fusion of the RNA-binding motif protein 15 (RBM15; aka OTT) and MKL1 (aka MAL) genes (Mercher et al., 2001; Ma et al., 2001b ). In contrast, many different cytogenetic abnormalities are observed in childhood non-DS AMKL, including t(10;11), which leads to the CALM-AF10 fusion (Abdelhaleem et al., 2007) , t(9;11), þ 8 or þ 21 (Barnard et al., 2006) . These latter cases share many features with t(1;22) leukemias, but present slightly later in life, at a median age of 2.2 years (Barnard et al., 2006) . Of note, all groups of children with non-DS AMKL show significantly inferior overall survival and event-free survival compared to children diagnosed with other myeloid leukemias (FAB M0-M5) or with DS-AMKL (Lange et al., 1998; Barnard et al., 2006; Rubnitz et al., 2007) .
Adult AMKL. Another class of aggressive megakaryocytic leukemias is adult AMKL. This is a rare malignancy that comprises nearly 1% of adult AML cases (Tallman et al., 2000; Pagano et al., 2002) . Similar to the other subtypes of AMKL, this leukemia is characterized by the excessive production of primitive megakaryoblasts within the bone marrow and extensive myelofibrosis. Peripheral blood features frequently include anemia and thrombocytopenia, in addition to circulating megakaryoblasts, which express plateletspecific antigens, such as CD41 and CD61, but lack myeloperoxidase or lymphoid antigens. Adult AMKL frequently arises in individuals who had an antecedent blood disorder or myelodysplastic syndrome (Oki et al., 2006) . Although some patients achieve complete remission, the long-term outcome is significantly worse for AMKL than other forms of adult AML, with a median survival of 40 weeks or less (Tallman et al., 2000; Pagano et al., 2002; Oki et al., 2006) .
To date, no specific chromosomal rearrangements or genetic mutations have been found in adult AMKL. In one study, it was noted that nearly 50% of patients had one or more cytogenetic abnormalities, including À5, À7, þ 8 or 11q involvement (Oki et al., 2006) . These findings partially explain the poor outcome of this subtype of AMKL, although the poor prognosis is not fully dependent on cytogenetic abnormalities. With respect to genetic mutations, multiple studies have now reported that the tyrosine kinases JAK2 or JAK3 are mutated in a subset of AMKL patients, although the mechanisms by which these mutations contribute to acute leukemia have not yet been elucidated (discussed below).
Transcriptional regulation in normal and transformed megakaryocytes
Leukemias often arise as a consequence of deregulation of transcription factors that are essential for normal development (Rosenbauer and Tenen, 2007) , such as mutations in RUNX1/AML1 and C/EBPA in AML, translocation of SCL in T-ALL, and mutations in GATA1 in DS-AMKL.
GATA-1. GATA-1 and its partner FOG-1 are absolutely required for normal development of megakaryocytes and platelets. Mice that lack GATA-1 expression specifically in the megakaryocyte lineage (GATA-1 low or GATA-1 knockdown mice) develop megakaryocytes, but they are abnormal in many respects (Shivdasani et al., 1997; Vyas et al., 1999; Vannucchi et al., 2002) . For example, they show reduced polyploidization, a failure to produce platelets, and a marked expansion both in vivo and when cultured in vitro. Of note, rescuing their polyploidization defect by ectopic expression of cyclin D1/cdk4 failed to restore platelet biosynthesis, confirming that polyploidization and terminal maturation can be uncoupled (Muntean et al., 2007) . The defect in GATA-1 low mice also extends to the progenitor stage, as MEPs isolated from GATA-1 low mice generate not only red blood cells and megakaryocytes, but also mast cells (Ghinassi et al., 2007) . This surprising observation shows that the level of GATA-1 is not only important in terminally differentiating cells, but also hematopoietic progenitors.
The interacting partner of GATA-1, FOG-1, is also essential for megakaryopoiesis, although it plays a more crucial role than GATA-1 in early megakaryocyte progenitors, as FOG-1-deficient mice do not generate any cells of the megakaryocyte lineage (Tsang et al., 1998) . Mice that express a GATA-1 mutant that fails to interact with FOG-1 show a phenotype that resembles that of GATA-1 knockdown mice, suggesting that FOG-1 has GATA-1-independent functions, likely mediated through GATA-2 (Chang et al., 2002) . Furthermore, mutations in the N-terminal zinc finger that led to the dissociation of the GATA-1/FOG-1 interaction, or to a decreased ability of GATA-1 to bind DNA, have been associated with a spectrum of benign hematologic diseases in humans, including dyserythropoietic anemia and thrombocytopenia (for a review, see Crispino, 2005) , gray platelet syndrome (Tubman et al., 2007) and congenital erythropoietic porphyria (Phillips et al., 2007) . Of note, there have been no reports of mutations in FOG-1 in human hematopoietic diseases. This may reflect the essential early role for FOG-1 in megakaryopoiesis or the redundancy of the multiple zinc fingers within FOG-1 that may compensate for any deficiency in one finger.
In addition to mutations in the N-finger of GATA1 in benign blood disorders, distinct mutations in the sequences encoding the N-terminal activation domain are found in patients with TMD and DS-AMKL (Muntean et al., 2006) . In all cases, the GATA1 mutations block expression of the full-length protein, but allow for expression of a shorter isoform named GATA-1s (Wechsler et al., 2002) . This short isoform retains the two zinc fingers and can bind DNA and interact with cofactors including FOG-1, but lacks the N-terminal transcriptional activation domain and thus is likely deficient in its ability to maintain the normal transcriptional program in megakaryocytes. Indeed, several recent studies have shown that although GATA-1s can promote terminal differentiation of megakaryocytes, it is unable to properly regulate the proliferation of fetal liver megakaryocyte progenitors (Kuhl et al., 2005; Li et al., 2005; Muntean and Crispino, 2005) . Thus, it appears that mutagenesis of GATA1 cooperates with trisomy 21 to promote the abnormal proliferation of megakaryocytes in TMD and DS-AMKL. For additional insights into this leukemia, the reader is directed to recent reviews of this topic (Izraeli, 2006; Vyas and Roberts, 2006; Vyas and Crispino, 2007) . RUNX1/AML1. RUNX1/AML1 has established functions in hematopoietic stem cell development, megakaryopoiesis and leukemia. In particular, the absence of RUNX1 has profound effects on the polyploidization and terminal maturation of megakaryocytes, leading to a significant reduction in polyploidization and platelet formation in vivo (Ichikawa et al., 2004; Growney et al., 2005; Putz et al., 2006) . Expression of the proper amount of RUNX1 is also essential for normal platelet homeostasis, as Runx1-heterozygous animals display a mild thrombocytopenia, which is accompanied by an inversion of the CD4( þ ) to CD8( þ ) T-cell ratio and a decrease in long-term repopulating hematopoietic stem cells (Sun and Downing, 2004) . RUNX1 gene rearrangements are involved in some of the recurring translocations associated with leukemia, while mutations are associated with familial platelet disorder with predisposition to AML and sporadic cases of AML (Nucifora and Rowley, 1995; McLean et al., 1996; Song et al., 1999; Osato et al., 1999; Preudhomme et al., 2000; Michaud et al., 2002; Peterson and Zhang, 2004) . Although mutations in RUNX1 were not found in patients with DS-AMKL (Wechsler et al., 2002) , altered gene dosage of RUNX1 may be involved in the development of AMKL. Indeed, several groups have speculated that increased dose of RUNX1 contributes to leukemia in DS (Osato and Ito, 2005; Yanagida et al., 2005; Langebrake et al., 2006) . In one study, transgenic overexpression of RUNX1, driven by the GATA-1 promoter, did not cause spontaneous leukemia, but did shorten the latency of leukemia development in BXH-2 mice and increase the frequency of tumors with a megakaryoblastic phenotype . Conversely, reduced expression of RUNX1 also facilitated leukemia in animals, as Runx1-heterozygous BXH-2 mice developed myeloid leukemias with a shortened latency . Furthermore, reduced expression of RUNX1 may contribute to the pathogenesis of human TMD and DS-AMKL (Bourquin et al., 2006) . Taken together, these studies suggest that dosage of RUNX1 must be tightly coordinated in vivo.
GFI-1B, NF-E2 and c-myb. Other transcription factors that contribute to megakaryopoiesis, as well as erythropoiesis, include GFI-1B, NF-E2 and c-myb. Gfi-1b is essential for terminal megakaryocyte maturation, as Gfi-1b-deficient fetal liver progenitors give rise to small, poorly formed megakaryocyte colonies comprised of cells that express significantly reduced levels of vonWillebrand factor, gpIIb, c-mpl and NF-E2 compared to wild-type cells (Saleque et al., 2002) . Interestingly, GFI-1B appears to be overexpressed in both erythroid and megakaryocytic human malignancies where it may contribute to the increased proliferation of leukemic cells (Elmaagacli et al., 2007) . Another transcriptional regulator that is essential for platelet biosynthesis is NF-E2, which promotes expression of mid-late stage megakaryocyte genes including b1-tubulin (Shivdasani et al., 1995; Chen et al., 2007) . Overexpression of NF-E2 may play a role in the progression of MPDs, including polycythemia vera (Goerttler et al., 2005) , although a strong association with megakaryocytic leukemias has not been found. Finally, c-myb also plays an essential role in megakaryocyte development. Suboptimal levels of c-myb favor the differentiation of megakaryocytes and macrophages (Emambokus et al., 2003) , and lossof-function mutations are also associated with excess megakaryopoiesis and increased platelet counts in animals (Carpinelli et al., 2004) . Point mutations in c-myb, however, are unlikely to be a common cause of human myelofibrosis (Steensma et al., 2006b) or megakaryocytic leukemia.
ETS family members. Several ETS proteins, including GABPa, ETS1, ETS2, ERG and Fli-1, are expressed in megakaryocytes and play key roles in megakaryocyte development. Although a role for Fli-1 in regulation of megakaryocyte genes has been well established , recent work has shown that GABPa is a regulator of early megakaryocyte-specific genes, including aIIb and c-mpl (Pang et al., 2006) . In addition, this study showed that the ratio of GABPa/Fli-1 decreases with megakaryocyte maturation, consistent with a dependence of late megakaryocyte-specific genes on Fli-1 for their expression. Similarly, another recent study has shown that ETS1 is involved in megakaryocyte development: ETS1 was found to increase during megakaryocyte maturation, and its overexpression was associated with enhanced differentiation and upregulation of GATA-2 and megakaryocyte-specific genes (Lulli et al., 2006) . ETS2 and ERG, which are localized to human chromosome 21, are also expressed within megakaryocytes. Aberrant expression of these genes may be involved in megakaryocytic leukemia in children with DS (Rainis et al., 2005) , but future studies are necessary to define the contribution of these factors to AMKL.
Transformation by translocation: OTT and MKL1 in pediatric AMKL
The majority of infant cases of AMKL are associated with the t(1;22), which results in fusion of RBM15, also known as one-twenty-two (OTT), to megakaryocyte leukemia (MKL1), also known as megakaryocytic acute leukemia (MAL) (Mercher et al., 2001; Ma et al., 2001a) . The RBM15/OTT partner contains three RNA recognition motifs (RRMs) and its C terminus is comprised of a 'spen paralogs and orthologs C-terminal' domain. This latter domain is derived from the Drosophila spen gene, which encodes an RRM-containing protein that can modulate both Hox function and Ras signaling (Wiellette et al., 1999; Chen and Rebay, 2000) . A related member of the Drosophila Spen family, SHARP, has been found to interact with RBP-Jk to repress transcription of Notch target genes, including HES-1, and thus inhibit signaling in the absence of activated Notch (Oswald et al., 2002) . A recent study has demonstrated that RBM15 itself can modulate Notch signaling by interacting with RBP-Jk within hematopoietic cells . Interestingly, the association of RBM15 with RBP-Jk enhanced Notchinduced HES promoter activity in hematopoietic cells, but inhibited promoter activity in non-hematopoietic cells. Consistent with a role in leukemogenesis, overexpression of RBM15 inhibited differentiation of the 32D myeloid cell line, whereas reducing its expression by shRNA-mediated knockdown-enhanced terminal differentiation of these cells. Furthermore, analysis of Rbm15/Ott conditionally deleted mice has revealed that Rbm15/Ott plays inhibitory roles in development of the myeloid, megakaryocytic and progenitor compartments and suggests that dysregulation of Ott-dependent pathways may contribute to infant AMKL (Raffel et al., 2007) . However, the specific role of RBM15 in megakaryocyte progenitors remains undefined and awaits further studies.
The notable features of the MKL1/MAL fusion partner include the presence of a SAP domain, which has been postulated to connect DNA to the nuclear scaffold, a C-terminal proline-rich region, and a glutamine-rich segment reminiscent of MLL family members. MKL1/MAL is weakly similar to myocardin throughout its length and shows high similarity in the SAP domain. Interestingly, MKL1/MAL has been found to physically interact with myocardin via conserved leucine zipper domains (Du et al., 2004) . MKL1/MAL functions as a potent transcriptional cofactor for serum response factor (SRF) (Cen et al., 2003) and also regulates SRF-dependent smooth muscle cell differentiation (Du et al., 2004) . These observations suggest that perhaps aberrant expression of SRFdependent genes, resulting from the translocation, contributes to AMKL. Of note, the RBM15-MKL1 fusion protein retains all the functional domains of both proteins and is predicted to aberrantly modulate chromatin organization, Hox differentiation pathways or extracellular signaling (Mercher et al., 2001) . Indeed, the RBM15-MKL1 fusion protein was able to activate a subset of SRF-dependent reporters to a much greater extent than MKL1 alone (Cen et al., 2003) . These findings suggest that the SRF co-activator activity of MKL1 is enhanced by its fusion to RBM15. However, there have not been any reports to date of the consequences of overexpression of the fusion protein in hematopoietic cells in vivo. Thus, future studies to uncover the mechanisms by which this fusion protein leads to aberrant expansion and differentiation of megakaryocytes are needed. Interestingly, a homolog of RBM15, RBM6, has been found as a fusion partner of CSF1R in the MKL1 cell line, although it has yet to be found in human megakaryocytic leukemia samples (Gu et al., 2007) . The presence of a second fusion containing the RBM motif suggests that perhaps aberrant regulation of Hox function and/or Ras signaling is behind these megakaryocytic diseases.
Signaling proteins influencing megakaryocyte development JAK/STAT signaling. The main physiologic mediator of megakaryocyte growth is thrombopoietin, whose receptor c-MPL is expressed on megakaryocytes (reviewed by (Kirito and Kaushansky, 2006) . Engagement of c-MPL by thrombopoietin then leads to activation of JAK kinases and their downstream effectors, including STAT3 and STAT5. Recently, activating mutations in c-MPL have been found associated with two human MPDs, myelofibrosis with myeloid metaplasia and essential thrombocythemia, at a frequency of about 5 and 1% of patients, respectively (Pardanani et al., 2006; Pikman et al., 2006) . Mutations in JAK2 are much more common in human MPDs, having been found associated with polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis as well as in rare cases of myelodysplastic syndrome, chronic myelomonocytic leukemia and atypical myeloid disorder (Baxter et al., 2005; Frohling et al., 2005; James et al., 2005; Kralovics et al., 2005; Levine et al., 2005; Zhao et al., 2005; Nelson and Steensma, 2006) . Of note, several studies have shown that JAK family members can be mutated in AMKL. For example, Jelinek et al. (2005) found the V617F JAK2 mutation in 2/11 patients with megakaryocytic AML, while Steensma et al. (2006a) identified the V617F JAK2 mutation in 3/27 AMKL samples. Recently, Walters et al. (2006) identified JAK3-activating mutations in the CMK cell line, which harbors a GATA1 mutation and was derived from a patient with DS-AMKL, as well as in 1 of 3 DS-AMKL samples and 1 of 16 non-DS AMKL sample. Interestingly, transplantation of bone marrow cells expressing the JAK3 A572V mutant induced several features of megakaryocytic leukemia in recipient animals, in addition to a T-cell lymphoproliferative disorder (Walters et al., 2006) . These findings raise the intriguing possibility that mutations in JAKs may facilitate the development of leukemia, although it is likely that additional genetic events are required to drive AMKL.
Src family kinases. Another class of signaling molecules that govern proliferation and growth is the Src kinase family. Within megakaryocytes, Lyn and Fyn are the most highly expressed family members and appear to act to negatively regulate megakaryopoiesis downstream of thrombopoietin signaling (Lannutti et al., 2003) . Evidence that supports this negative role for Src family kinases (SFKs) include the observation that Lynnull mice show increased formation of megakaryocytes in vivo, and these megakaryocytes reached a higher ploidy state when compared to those of wild-type littermates (Lannutti et al., 2006) . To date, misexpression or mutations in these genes has not been associated with megakaryocytic malignancies, but perhaps their dysregulation will be found associated with a subset of AMKL cases.
Conclusions and future directions
Erythroid cells and megakaryocytes share many common features, but in general the events that led to malignant transformation appear to be distinct between the two lineages. For example, mutagenesis of GATA1 is exclusively associated with megakaryocytic leukemia, although maturation of the erythroid lineage is certainly affected by non-leukemic, somatic GATA1 mutations. Likewise, integration of the Friend virus or misexpression of PU.1 leads to transformation of erythroid, but not megakaryocyte, progenitors in animals.
Going forward, the challenges for researchers in the field of erythroid and megakaryocytic leukemia include deciphering the specific mechanisms by which known genetic alterations, including mutagenesis of GATA1 or JAK2, and fusion of the RBM15 and MKL1 proteins, contribute to transformation. The dual approach of mouse modeling and analysis of patient samples should provide new insights to these diseases, although patient studies are hampered by the rarity of these diseases. Furthermore, since the prognoses for patients with erythroleukemia and AMKL (apart from DS-AMKL) are very poor, another great challenge for researchers is to develop novel therapeutics that specifically target these leukemias. Perhaps by first improving our understanding of the molecular nature of these diseases, we will be better positioned to design improved therapies for patients.
